Shanghai Henlius Biotech to join Hang Seng Composite Index from Sept. 7PUBT·2 days ago, 06:31 AM02696-5.17%
Shanghai Henlius Biotech IFRS profit rises 10.33% to RMB 430.4 million in H1 FY26; revenue increases 27.3% to RMB 3.59 billionPUBT·2 days ago, 06:25 AM02696-5.17%
Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars PlatformPR Newswire·Aug 16 at 11:08 PMSDZNY+0.60%02696-5.17%
HENLIUS Reaches Global Strategic Partnership With Sandoz, Invoiceable Amt Expected to Reach USD100.5M This YearAASTOCKS News·Aug 16 at 08:06 PM02696-5.17%SDZNY+0.60%
Henlius Strikes Global Biosimilar Alliance with SandozTip Ranks·Aug 16 at 07:09 PM02696-5.17%SDZNY+0.60%
Sandoz partners with Henlius on up to 10 biosimilars in USD 322 million dealPUBT·Aug 16 at 07:00 PMSDZNY+0.60%02696-5.17%
Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform | SDZNY Stock NewsStockTitan·Aug 16 at 03:08 PM02696-5.17%SDZNY+0.60%
Shanghai Henlius Biotech (SEHK:2696) Advances Oncology Pipeline, Is It Still 64% Below Fair Value?Simplywall·Aug 9 at 06:33 PM02696-5.17%
Shanghai Henlius says China NMPA clears HLX43-bevacizumab trial in advanced solid tumorsPUBT·Jul 31 at 03:31 AM02696-5.17%
Shanghai Henlius Biotech Grants New Share Options and RSUs to Strengthen IncentivesTip Ranks·Jul 17 at 09:37 AM02696-5.17%
Henlius Doses First Patient in Global Trial of Nivolumab Biosimilar HLX18Tip Ranks·Jul 16 at 03:40 AM02696-5.17%
Shanghai Henlius says China NMPA clears Phase 1 trial of HLX37 with chemo or HLX43 in solid tumorsPUBT·Jul 10 at 03:31 AM02696-5.17%
Henlius Doses First Patient in Phase 1 Trial for Cetuximab Biosimilar HLX05-NTip Ranks·Jul 8 at 04:37 AM02696-5.17%
Shanghai Henlius doses first patient in Phase 1 trial of cetuximab biosimilar HLX05-N in ChinaPUBT·Jul 8 at 04:25 AM02696-5.17%
Is Shanghai Henlius Biotech (SEHK:2696) Pricey Or Undervalued After Its Canada Denosumab Launch?Simplywall·Jul 2 at 07:04 AM02696-5.17%
